We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

News · December 22, 2021

Molnupiravir Cuts Risk for Severe COVID-19 Illness in Adults

Risk for hospitalization or death lower in at-risk adults with mild-to-moderate COVID-19 receiving oral therapy with molnupiravir versus placebo



Further Reading